Food and Drug Administration/Xavier University Global Medical Device Conference; Public Conference, 8327-8328 [2015-03116]
Download as PDF
tkelley on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 31 / Tuesday, February 17, 2015 / Notices
always be published quickly enough to
provide timely notice. Therefore, you
should always check the Agency’s Web
site at https://www.fda.gov/Advisory
Committees/default.htm and scroll
down to the appropriate advisory
committee meeting link, or call the
advisory committee information line to
learn about possible modifications
before coming to the meeting.
Agenda: On February 20, 2015, the
committee will discuss, make
recommendations, and vote on
information regarding the premarket
approval application (PMA) for the
Superion InterSpinous Spacer device
sponsored by Vertiflex Inc. The
proposed indication for use for the
Superion InterSpinous Spacer device, as
stated in the PMA, is as follows: The
Superion InterSpinous Spacer (the
Superion ISS) is intended to treat
skeletally mature patients suffering from
pain, numbness, and/or cramping in the
legs (neurogenic intermittent
claudication) secondary to a diagnosis
of moderate lumbar spinal stenosis,
with or without grade 1
spondylolisthesis, confirmed by x ray,
magnetic resonance imaging, and/or
computed tomography evidence of
thickened ligamentum flavum,
narrowed lateral recess, and/or central
canal or foraminal narrowing. The
Superion ISS is indicated for those
patients with impaired physical
function who experience relief in
flexion from symptoms of leg/buttock/
groin pain, numbness, and/or cramping,
with or without back pain. The
Superion ISS may be implanted at one
or two adjacent lumbar (L) levels in
patients in whom treatment is indicated
at no more than two levels, from L1 to
L5.
The meeting was originally scheduled
for December 12, 2014. The meeting
date is being postponed from December
12, 2014, until February 20, 2015, due
to FDA needing additional time to
review information supplied by
sponsor.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
VerDate Sep<11>2014
16:51 Feb 13, 2015
Jkt 235001
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before February 18, 2015.
Oral presentations from the public will
be scheduled between approximately 1
p.m. and 2 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before February
13, 2015. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by February 17, 2015.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Anne Marie
Williams at Annmarie.Williams@
fda.hhs.gov or 301–796–5966 at least 7
days in advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
FDA regrets that it was unable to
publish this notice 15 days prior to the
February 20, 2015, Orthopaedic and
Rehabilitation Panel of the Medical
Devices Advisory Committee meeting.
Because the Agency believes there is
some urgency to bring these issues to
public discussion and qualified
members of the Orthopaedic and
Rehabilitation Panel of the Medical
Devices Advisory Committee were
available at this time, the Commissioner
of Food and Drugs concluded that it was
in the public interest to hold this
meeting even if there was not sufficient
time for the customary 15-day public
notice.
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
8327
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: February 10, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015–03155 Filed 2–13–15; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2015–N–0001]
Food and Drug Administration/Xavier
University Global Medical Device
Conference; Public Conference
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public conference.
The Food and Drug Administration
(FDA) Cincinnati District, in
cosponsorship with Xavier University,
is announcing a public conference
entitled ‘‘FDA/Xavier University Global
Medical Device Conference (MedCon).’’
This 3-day public conference includes
presentations from key FDA officials
and industry experts with small group
breakout sessions. The conference is
intended for companies of all sizes and
employees at all levels.
DATES: Dates and Times: The public
conference will be held on May 6, 2015,
from 8:30 a.m. to 5 p.m.; May 7, 2015,
from 8:30 a.m. to 5 p.m.; and May 8,
2015, from 8:30 a.m. to 12:30 p.m.
Location: The public conference will
be held on the campus of Xavier
University, 3800 Victory Pkwy.,
Cincinnati, OH 45207, 513–745–3016.
Contact Persons: For information
regarding this notice: Gina Brackett,
Food and Drug Administration, 6751
Steger Dr., Cincinnati, OH 45237, 513–
679–2700, FAX: 513–679–2771, email:
gina.brackett@fda.hhs.gov.
For information regarding the
conference and registration: Mason
Rick, Xavier University, 3800 Victory
Pkwy., Cincinnati, OH 45207–5471,
513–745–3016, email:
rickm@xavier.edu, or visit https://
www.XavierMedCon.com.
Registration: There is a conference
registration fee which covers the cost of
the presentations, training materials,
receptions, breakfasts, and lunches for
the 3 days of the conference. Advanced
registration begins February 6, 2015.
Standard registration begins March 6,
2015. There will be onsite registration.
The cost of registration is as follows:
E:\FR\FM\17FEN1.SGM
17FEN1
8328
Federal Register / Vol. 80, No. 31 / Tuesday, February 17, 2015 / Notices
TABLE 1—REGISTRATION FEES 1
Advanced rate
(2/6/15 to 3/5/15)
Attendee type
Industry ........................................................................................................................................................
Small Business (<100 Employees) .............................................................................................................
Startup Manufacturer ...................................................................................................................................
Academic .....................................................................................................................................................
FDA/Government Employee ........................................................................................................................
tkelley on DSK3SPTVN1PROD with NOTICES
1 The
$1,495
1,000
250
250
Free
Standard rate
(after 3/5/15)
$1,695
1,200
300
300
Free
following forms of payment will be accepted: American Express, Visa, MasterCard, and company checks.
To register online for the public
conference, please visit the
‘‘Registration’’ link on the conference
Web site at https://
www.XavierMedCon.com. FDA has
verified the Web site address, but is not
responsible for subsequent changes to
the Web site after this document
publishes in the Federal Register.
To register by mail, please send your
name, title, firm name, address,
telephone, email, and payment
information for the fee to Xavier
University, Attention: Mason Rick, 3800
Victory Pkwy., Cincinnati, OH 45207–
5471. An email will be sent confirming
your registration.
Attendees are responsible for their
own accommodations. The conference
headquarters hotel is the Downtown
Hilton Cincinnati Netherland Plaza, 35
West Fifth St., Cincinnati, OH 45202,
513–421–9100. Special conference block
rates are available through April 16,
2015. To make reservations online,
please visit the ‘‘Venue/Logistics’’ link
at https://www.XavierMedCon.com.
If you need special accommodations
due to a disability, please contact Mason
Rick (see Contact Persons) at least 7
days in advance of the conference.
SUPPLEMENTARY INFORMATION: The
public conference helps fulfill the
Department of Health and Human
Services’ and FDA’s important mission
to protect the public health. The
conference will provide those engaged
in FDA-regulated medical devices (for
humans) with information on the
following topics:
• Center Director Corner: Strategic
Priorities for 2015 and Beyond
• Office of Compliance Strategic
Priorities
• Advancements in Medical Device
Software Technology
• Understanding and Preparing for the
Revision of ISO13485
• Update from FDA’s Office of
Combination Products
• Unique Device Identification—
Implementation
• FDA Inspections and Insights
• Understanding the Current Activities
of the International Medical Device
Regulators Forum
VerDate Sep<11>2014
16:51 Feb 13, 2015
Jkt 235001
• European Union Medical Device/In
Vitro Diagnostics Regulation Review
• Update from the Office of Device
Evaluation
• Regulatory Submissions and
Strategies
• Complaints, Corrective and
Preventive Actions, and Recalls
• Regulatory Challenges in Asia
• Action Plan Writing
• Lunch Networking by Topic
FDA has made education of the drug
and device manufacturing community a
high priority to help ensure the quality
of FDA-regulated drugs and devices.
The conference helps to achieve
objectives set forth in section 406 of the
Food and Drug Administration
Modernization Act of 1997 (21 U.S.C.
393), which includes working closely
with stakeholders and maximizing the
availability and clarity of information to
stakeholders and the public. The
conference also is consistent with the
Small Business Regulatory Enforcement
Fairness Act of 1996 (Public Law 104–
121) by providing outreach activities by
Government agencies to small
businesses.
Dated: February 10, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015–03116 Filed 2–13–15; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2015–N–0001]
In Motion: Science Transforming
Policy in Food, Drug, and Medical
Device Regulation
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public conference.
The Food and Drug Administration
(FDA) Detroit District Office, in
cosponsorship with the Association of
Food and Drug Officials (AFDO), is
announcing a public conference entitled
‘‘In Motion: Science Transforming
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
Policy in Food, Drug, and Medical
Device Regulation.’’ The conference
Web site is https://indy.afdo.org/. This
conference is intended to provide
information about FDA food, drug, and
device regulation to the regulated
industry.
Date and Time: The public conference
will be held on June 20 to 24, 2015.
Times will vary.
Location: The conference will be held
at the Sheraton Indianapolis Hotel at
Keystone Crossing, Indianapolis, 8787
Keystone Crossing, Indianapolis, IN
46240, 317–846–2700 or toll-free 888–
627–7814; www.sheratonindianapolis
keystonecrossing.com.
Attendees are responsible for their
own accommodations. To make
reservations at the Sheraton
Indianapolis Hotel at the reduced
conference rate, please call 303–295–
1234 and mention ‘‘AFDO Conference’’
before May 20, 2015. All the hotel
information needed to call or reserve
online is available at https://
indy.afdo.org/hotel.html.
AFDO contact information: Randy
Young, Association of Food and Drug
Officials, 2550 Kingston Rd., suite 311,
York, PA 17402, 717–757–2888, FAX:
717–650–3650, email: ryoung@afdo.org.
Registration: You are encouraged to
register by May 20, 2015. The AFDO
registration fees cover the cost of
facilities, materials, and breaks. Seats
are limited; therefore, please submit
your registration as soon as possible.
Course space will be filled in order of
receipt of registration. Those accepted
into the course will receive
confirmation. Registration will close
after the course is filled. Registration at
the site is not guaranteed but may be
possible on a space available basis on
the day of the conference beginning at
8 a.m. The cost of registration follows:
Cost of Registration:
Member—$475.00
Non-Member—$575.00
*A $100 late fee will be added if
payment is postmarked after June 1,
2015.
If you need special accommodations
due to a disability, please contact Randy
Young (see AFDO contact information)
E:\FR\FM\17FEN1.SGM
17FEN1
Agencies
[Federal Register Volume 80, Number 31 (Tuesday, February 17, 2015)]
[Notices]
[Pages 8327-8328]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-03116]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2015-N-0001]
Food and Drug Administration/Xavier University Global Medical
Device Conference; Public Conference
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public conference.
-----------------------------------------------------------------------
The Food and Drug Administration (FDA) Cincinnati District, in
cosponsorship with Xavier University, is announcing a public conference
entitled ``FDA/Xavier University Global Medical Device Conference
(MedCon).'' This 3-day public conference includes presentations from
key FDA officials and industry experts with small group breakout
sessions. The conference is intended for companies of all sizes and
employees at all levels.
DATES: Dates and Times: The public conference will be held on May 6,
2015, from 8:30 a.m. to 5 p.m.; May 7, 2015, from 8:30 a.m. to 5 p.m.;
and May 8, 2015, from 8:30 a.m. to 12:30 p.m.
Location: The public conference will be held on the campus of
Xavier University, 3800 Victory Pkwy., Cincinnati, OH 45207, 513-745-
3016.
Contact Persons: For information regarding this notice: Gina
Brackett, Food and Drug Administration, 6751 Steger Dr., Cincinnati, OH
45237, 513-679-2700, FAX: 513-679-2771, email:
gina.brackett@fda.hhs.gov.
For information regarding the conference and registration: Mason
Rick, Xavier University, 3800 Victory Pkwy., Cincinnati, OH 45207-5471,
513-745-3016, email: rickm@xavier.edu, or visit https://www.XavierMedCon.com.
Registration: There is a conference registration fee which covers
the cost of the presentations, training materials, receptions,
breakfasts, and lunches for the 3 days of the conference. Advanced
registration begins February 6, 2015. Standard registration begins
March 6, 2015. There will be onsite registration. The cost of
registration is as follows:
[[Page 8328]]
Table 1--Registration Fees \1\
------------------------------------------------------------------------
Advanced rate (2/ Standard rate
Attendee type 6/15 to 3/5/15) (after 3/5/15)
------------------------------------------------------------------------
Industry.......................... $1,495 $1,695
Small Business (<100 Employees)... 1,000 1,200
Startup Manufacturer.............. 250 300
Academic.......................... 250 300
FDA/Government Employee........... Free Free
------------------------------------------------------------------------
\1\ The following forms of payment will be accepted: American Express,
Visa, MasterCard, and company checks.
To register online for the public conference, please visit the
``Registration'' link on the conference Web site at https://www.XavierMedCon.com. FDA has verified the Web site address, but is not
responsible for subsequent changes to the Web site after this document
publishes in the Federal Register.
To register by mail, please send your name, title, firm name,
address, telephone, email, and payment information for the fee to
Xavier University, Attention: Mason Rick, 3800 Victory Pkwy.,
Cincinnati, OH 45207-5471. An email will be sent confirming your
registration.
Attendees are responsible for their own accommodations. The
conference headquarters hotel is the Downtown Hilton Cincinnati
Netherland Plaza, 35 West Fifth St., Cincinnati, OH 45202, 513-421-
9100. Special conference block rates are available through April 16,
2015. To make reservations online, please visit the ``Venue/Logistics''
link at https://www.XavierMedCon.com.
If you need special accommodations due to a disability, please
contact Mason Rick (see Contact Persons) at least 7 days in advance of
the conference.
SUPPLEMENTARY INFORMATION: The public conference helps fulfill the
Department of Health and Human Services' and FDA's important mission to
protect the public health. The conference will provide those engaged in
FDA-regulated medical devices (for humans) with information on the
following topics:
Center Director Corner: Strategic Priorities for 2015 and
Beyond
Office of Compliance Strategic Priorities
Advancements in Medical Device Software Technology
Understanding and Preparing for the Revision of ISO13485
Update from FDA's Office of Combination Products
Unique Device Identification--Implementation
FDA Inspections and Insights
Understanding the Current Activities of the International
Medical Device Regulators Forum
European Union Medical Device/In Vitro Diagnostics Regulation
Review
Update from the Office of Device Evaluation
Regulatory Submissions and Strategies
Complaints, Corrective and Preventive Actions, and Recalls
Regulatory Challenges in Asia
Action Plan Writing
Lunch Networking by Topic
FDA has made education of the drug and device manufacturing
community a high priority to help ensure the quality of FDA-regulated
drugs and devices. The conference helps to achieve objectives set forth
in section 406 of the Food and Drug Administration Modernization Act of
1997 (21 U.S.C. 393), which includes working closely with stakeholders
and maximizing the availability and clarity of information to
stakeholders and the public. The conference also is consistent with the
Small Business Regulatory Enforcement Fairness Act of 1996 (Public Law
104-121) by providing outreach activities by Government agencies to
small businesses.
Dated: February 10, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-03116 Filed 2-13-15; 8:45 am]
BILLING CODE 4164-01-P